Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces positive data from pre-clinical studies with AP31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent AF recurrence. Acesion aims to develop a […]
Cambridge, UK, April 25, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023. Read more…
Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes Strong overexpression in tumors combined with low expression levels in normal human tissues makes uPARAP an attractive candidate for therapeutic targeting of sarcomas by antibody-drug conjugates (ADCs) Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the […]
Brighton, United Kingdom – 4 April 2023 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, to successfully colonise the gut following administration […]
Data from GLP[i] animal studies demonstrate safety of second-generation DSR[ii] product (DSR 2.0) Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and IND[iii] filing to US FDA expected in Q1 2023 Planning to start MOJAVE, a US Phase 1/2a randomized controlled multi-center study of DSR 2.0, in Q2 2023 Ghent, Belgium – 08 February 2023 – Sequana […]
